Zobrazeno 1 - 10
of 34
pro vyhledávání: '"Reem Karmali"'
Autor:
Timothy S. Fenske, Jin Guo, Brian T. Hill, Natalie S Grover, Krithika Shanmugasundaram, Madelyn Burkart, Brad S. Kahl, Stefan K. Barta, J. Switchenko, Alexey V. Danilov, Subir Goyal, Mehdi Hamadani, Max J. Gordon, Christopher R. Flowers, Oscar Calzada, Peter Martin, David A. Bond, Jonathon B. Cohen, Yazeed Sawalha, Nilanjan Ghosh, Steven I. Park, Kristie A. Blum, James N. Gerson, Bhaskar Kolla, Reem Karmali, Stephanie Mathews, Michael C. Churnetski, Talha Badar, Veronika Bachanova, Mary Malecek, Narendranath Epperla
Publikováno v:
Eur J Haematol
INTRODUCTION: While most patients with mantle cell lymphoma (MCL) receive therapy shortly after diagnosis, a subset of patients with indolent-behaving disease can safely defer treatment. In this subgroup, we evaluated the importance of treatment inte
Autor:
Narendranath Epperla, Nicolas Martinez-Calle, Veronika Bachanova, David Peace, Seo-Hyun Kim, Maryam Sarraf Yazdy, Andreas K. Klein, Andrew M. Evens, Neil Palmisiano, Scott E. Smith, Catherine Zhu, Manali Kamdar, Adam Zayac, Izidore S. Lossos, Catherine Diefenbach, Nadia Khan, Elizabeth H Phillips, Matthew A. Lunning, Alessia Dalla Pria, Knut B. Smeland, Chan Yoon Cheah, Adam J. Olszewski, Peter Martin, Anna Santarsieri, Kirsten M Boughan, Umar Farooq, Alexey V. Danilov, Graham P. Collins, Tycel Phillips, Reem Karmali, Alina S. Gerrie, Silvia Montoto, Stephen D. Smith, Shireen Kassam, Kevin A. David, Mark Bower, Deepa Jagadeesh, Tarec Christoffer El-Galaly, Kate Cwynarski, Suchitra Sundaram, Xiao Yin Zhang, Vaishalee P. Kenkre, Fredrik Ellin, Tatyana Feldman, Lasse Hjort Jakobsen, Craig A. Portell, Seema Naik, Nishitha Reddy, Kristie A. Blum
Publikováno v:
J Clin Oncol
Olszewski, A J, Jakobsen, L H, Collins, G P, Cwynarski, K, Bachanova, V, Blum, K A, Boughan, K M, Bower, M, Dalla Pria, A, Danilov, A, David, K A, Diefenbach, C, Ellin, F, Epperla, N, Farooq, U, Feldman, T A, Gerrie, A S, Jagadeesh, D, Kamdar, M, Karmali, R, Kassam, S, Kenkre, V P, Khan, N, Kim, S-H, Klein, A K, Lossos, I S, Lunning, M A, Martin, P, Martinez-Calle, N, Montoto, S, Naik, S, Palmisiano, N, Peace, D, Phillips, E H, Phillips, T J, Portell, C A, Reddy, N, Santarsieri, A, Sarraf Yazdy, M, Smeland, K B, Smith, S E, Smith, S D, Sundaram, S, Zayac, A S, Zhang, X-Y, Zhu, C, Cheah, C Y, El-Galaly, T C, Evens, A M & The Burkitt Lymphoma International Prognostic Index consortium 2021, ' Burkitt Lymphoma International Prognostic Index ', Journal of Clinical Oncology, vol. 39, no. 10, JCO2003288, pp. 1129-1138 . https://doi.org/10.1200/JCO.20.03288
Olszewski, A J, Jakobsen, L H, Collins, G P, Cwynarski, K, Bachanova, V, Blum, K A, Boughan, K M, Bower, M, Dalla Pria, A, Danilov, A, David, K A, Diefenbach, C, Ellin, F, Epperla, N, Farooq, U, Feldman, T A, Gerrie, A S, Jagadeesh, D, Kamdar, M, Karmali, R, Kassam, S, Kenkre, V P, Khan, N, Kim, S-H, Klein, A K, Lossos, I S, Lunning, M A, Martin, P, Martinez-Calle, N, Montoto, S, Naik, S, Palmisiano, N, Peace, D, Phillips, E H, Phillips, T J, Portell, C A, Reddy, N, Santarsieri, A, Sarraf Yazdy, M, Smeland, K B, Smith, S E, Smith, S D, Sundaram, S, Zayac, A S, Zhang, X-Y, Zhu, C, Cheah, C Y, El-Galaly, T C, Evens, A M & The Burkitt Lymphoma International Prognostic Index consortium 2021, ' Burkitt Lymphoma International Prognostic Index ', Journal of Clinical Oncology, vol. 39, no. 10, JCO2003288, pp. 1129-1138 . https://doi.org/10.1200/JCO.20.03288
PURPOSE Burkitt lymphoma (BL) has unique biology and clinical course but lacks a standardized prognostic model. We developed and validated a novel prognostic index specific for BL to aid risk stratification, interpretation of clinical trials, and tar
Autor:
Adam J. Olszewski, Brad S. Kahl, Christopher Del Prete, Thomas A Ollila, Victor M. Orellana-Noia, Craig A. Portell, Jun Lee, A. Mccook, Hanan Alharthy, Benjamin Echalier, Paolo F. Caimi, Natalie S Grover, Hayder Saeed, Daniel J. Landsburg, Ajay Major, Alexandra E Rojek, Jieqi Liu, Timothy Fu, Ranjana H. Advani, Yuxin Liu, Manali Kamdar, Stephen E. Spurgeon, Harsh Shah, Daniel R Reed, Emily C. Ayers, Jennie Y. Law, Jeremy M Sen, Jonathon B. Cohen, Jeffrey M. Switchenko, Reem Karmali, Scott F. Huntington, Timothy J Voorhees, Anson Snow, Julio C. Chavez, Frederick Lansigan, Jason T. Romancik, Mary-Kate Malecek, Brain T Hill, Christian M Barlow, Amy A. Ayers, Amulya Yellala, Mohammad Ahsan Sohail, Nadia Khan, Aleksandr Lazaryan, Deborah M. Stephens, Marcus P Watkins, Michael A. Spinner, Shazia Nakhoda, Kevin A. David, Avyakta Kallam, Odeth Barrett-Campbell, Vikram Raghunathan, Sonali M. Smith
Publikováno v:
Blood
Prophylaxis is commonly used to prevent central nervous sy stem (CNS) relapse in diffuse large B-cell lymphoma (DLBCL), with no clear standard of care. We retrospectively evaluated 1162 adult patients across 21 US academic centers with DLBCL or simil
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e6766d28bba0053ec72908d58e3a0859
https://europepmc.org/articles/PMC8777199/
https://europepmc.org/articles/PMC8777199/
Autor:
Reem Karmali
Publikováno v:
Hematology Am Soc Hematol Educ Program
Innovations in immuno-oncology for lymphomas have outpaced therapeutic developments in any other cancer histology. In the 1990s, rituximab, a CD20 monoclonal antibody, drastically changed treatment paradigms for B-cell non-Hodgkin lymphomas (B-NHLs).
Autor:
David A. Bond, Angel Mier Hicks, Amir Behdad, Pallawi Torka, Daniel J. Landsburg, Nina D. Wagner-Johnston, Julio C. Chavez, Kami J. Maddocks, Reem Karmali, Rawan Faramand, Radhakrishnan Ramchandren, Emily C. Ayers, Madeira Curry, Dipenkumar Modi, L. Jeffrey Medeiros, Sarit Assouline, Shaoying Li
Publikováno v:
British Journal of Haematology. 189:313-317
While patients with double-hit lymphoma (DHL) are now frequently treated with intensive front-line immunochemotherapy, outcomes for those who fail these regimens and subsequently receive curative-intent second-line immunochemotherapy are unknown. We
Autor:
Angel Mier Hicks, Julio C. Chavez, Amir Behdad, Emily C. Ayers, Jonathon B. Cohen, Daniel J. Landsburg, Catherine Diefenbach, Victor M. Orellana-Noia, Bita Fakhri, Michael C. Churnetski, Anshu Giri, Shaoying Li, Kami J. Maddocks, Rawan Faramand, Brian T. Hill, Christina Howlett, Jennifer E Amengual, Helen Ma, Craig A. Portell, Brian T. Hess, Yang Liu, Reem Karmali, Pallawi Torka, Adam J. Olszewski, Samuel Cytryn, Sarit Assouline, Madeira Curry, Radhakrishnan Ramchandren, Nishitha Reddy, Brad S. Kahl, Stefan K. Barta, Nina D. Wagner-Johnston, L. Jeffrey Medeiros, Dipenkumar Modi, David A. Bond, Ashwin Chandar, Lori A. Leslie, Dhruvika Mukhija, Kevin A. David, Sunita Nathan
Publikováno v:
Cancer. 126:293-303
BACKGROUND Salvage immunochemotherapy followed by high-dose chemotherapy and autologous stem cell transplantation is the standard-of-care second-line treatment for patients with relapsed/refractory diffuse large B-cell lymphoma after first-line R-CHO
Autor:
Max J. Gordon, Timothy S. Fenske, Peter Martin, Natalie S Grover, Mary Malecek, Bhaskar Kolla, Brian T. Hill, Jeffrey M. Switchenko, Madelyn Burkart, Reem Karmali, Kami J. Maddocks, Jin Guo, David A. Bond, Stephanie Mathews, Narendranath Epperla, Michael C. Churnetski, Alexey V. Danilov, Talha Badar, Nilanjan Ghosh, Jonathon B. Cohen, Subir Goyal, Steven I. Park, Kristie A. Blum, Krithika Shanmugasundaram, James N. Gerson, Veronika Bachanova, Brad S. Kahl, Stefan K. Barta, Christopher R. Flowers, Yazeed Sawalha, Mehdi Hamadani
Publikováno v:
Am J Hematol
Clinical outcomes and predictors of survival in patients with newly diagnosed mantle cell lymphoma (MCL) treated in the rituximab era (2000-2015) at 12 US academic centers were assessed to identify determinants of survival across age groups. Objectiv
Autor:
Kwang Woo Ahn, Mohamed A. Kharfan-Dabaja, Nirav N. Shah, Farhad Khimani, Praveen Ramakrishnan Geethakumari, Sairah Ahmed, Yue Chen, Sachiko Seo, Nilanjan Ghosh, Narendranath Epperla, Mehdi Hamadani, Sanghee Hong, Amer Beitinjaneh, Pashna N. Munshi, Tim Prestidge, Leona Holmberg, Victor A. Chow, Michael Scordo, Yago Nieto, Natalie S Grover, Umar Farooq, Nada Hamad, Reem Karmali, Gerhard C. Hildebrandt, Andrew R. Rezvani, Jean A. Yared, Antonio Jimenez-Jimenez, Maxwell M. Krem, Bhagirathbhai Dholaria, Evgeny Klyuchnikov, Craig S. Sauter, David J. Inwards, Peter A. Riedell, Trent P Wang, Farrukh T. Awan, Alex F. Herrera, Andy I. Chen, Melhem Solh, Vaishalee P. Kenkre
Publikováno v:
JAMA Oncol
IMPORTANCE: Primary central nervous system lymphoma (PCNSL) requires induction and consolidation to achieve potential cure. High-dose therapy and autologous hematopoietic cell transplant (AHCT) is an accepted and effective consolidation strategy for
Autor:
Farrukh T. Awan, Pashna N. Munshi, Melhem Solh, Siddhartha Ganguly, Kwang Woo Ahn, Usama Gergis, David J. Inwards, Carlos Litovich, Amir Steinberg, Timothy S. Fenske, Ayman Saad, Ravi Vij, William A. Wood, Sonali M. Smith, Mohamed A. Kharfan-Dabaja, Nirav N. Shah, Lazaros J. Lekakis, Mehdi Hamadani, Anna Sureda, Alexsandr Lazaryan, Sunita Nathan, Reem Karmali
Publikováno v:
Blood Cancer Journal, Vol 11, Iss 4, Pp 1-1 (2021)
Blood Cancer Journal
Blood Cancer Journal
Allogeneic hematopoietic cell transplantation (allo-HCT) is a curative therapy for relapsed/refractory and high-risk non-Hodgkin lymphoma (NHL). However, no large studies have evaluated allo-HCT utilization in elderly NHL patients (≥65 years). Usin
Autor:
Pamela B. Allen, Ranjana H. Advani, Kaitlyn O'Shea, Hatice Savas, Robert Eisner, Leo I. Gordon, Joan S. Chmiel, Brett Alan Palmer, Reem Karmali, Jane N. Winter, Jeffrey Bearden, Barbara Pro, Robert Bayer, Andrew M. Evens, Gary Dillehay, Eric Mou
Publikováno v:
Blood
Pembrolizumab, a humanized IgG4 monoclonal antibody targeting programmed death-1 protein, has demonstrated efficacy in relapsed/refractory classical Hodgkin lymphoma (cHL). To assess the complete metabolic response (CMR) rate and safety of pembrolizu
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::aad788f725d552cec579bf7aeaeec958
https://europepmc.org/articles/PMC7955404/
https://europepmc.org/articles/PMC7955404/